Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
36.14
+0.51 (1.43%)
At close: Aug 14, 2026, 4:00 PM EDT
36.23
+0.09 (0.25%)
After-hours: Aug 14, 2026, 7:34 PM EDT
Neurogene Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
131
Market Cap
723.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 174.48M |
| Gyre Therapeutics | 109.82M |
| CytomX Therapeutics | 18.30M |
| Attovia Therapeutics | 1.35M |
| Allogene Therapeutics | 22.00K |
NGNE News
- 4 days ago - Neurogene Slides: Corporate presentation - Filings
- 4 days ago - Neurogene reports Q2 EPS ($1.53), consensus ($1.38) - TheFly
- 4 days ago - Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates - Business Wire
- 4 days ago - Neurogene Earnings release: Q2 2026 - Filings
- 4 days ago - Neurogene Quarterly report: Q2 2026 - Filings
- 10 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Neurogene prices 3.5M shares at $30.00 in public offering - TheFly
- 6 weeks ago - Neurogene Inc. Announces Pricing of $125 Million Public Offering - Business Wire